



# Preliminary Programme

European Congress of  
Clinical Microbiology  
and Infectious Diseases

**Barcelona, Spain**  
27–30 April 2024

**ECCMID**



**34th**

[www.eccmid.org](http://www.eccmid.org)

# Disclaimer & Dates

## Disclaimer

The following ECCMID 2024 scientific programme is preliminary only, and does not represent the entirety of the ECCMID invited programme. Speakers and chairpersons will be added to sessions as they are confirmed.

Integrated symposia from industry partners will also be published once confirmed in the website section dedicated to sponsors.

The ECCMID 2024 scientific programme is expected to be finalised in March of 2024.

---

## Present your research and be part of ECCMID!

ECCMID has become one of the most comprehensive and influential congresses in the field of infection and an exciting networking place bringing together >16,000 colleagues from all over the world. Share and discuss your research with colleagues from around the world.

---

## Abstract submission

Regular abstracts can be submitted from 16 October 2023 to 29 November 2023, 16:00 CET.

Late breaker abstracts submission will open in late January 2024.

---

## Registration

<b>Early Bird fee</b>	until 14.02.2024
<b>Regular fee</b>	from 15.02.2024 to 13.03.2024
<b>Late fee</b>	from 14.03.2024

# Preliminary Programme

## Keynote Lectures

### Keynote Lecture

#### Viral infections in stem cell transplantation: a lifetime journey

##### *Per Ljungman (Stockholm, Sweden)*



Per Ljungman is currently senior physician in the Dept. of Cellular Therapy and Allogeneic Stem Cell Transplantation and emeritus professor at Karolinska Institutet. He received his MD and PhD degrees from Karolinska Institutet and performed a post doctoral fellowship at the Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA. He is board qualified in internal medicine and hematology. His research interests have been virus infections in the severely immunocompromised host represented by patients undergoing allogeneic stem cell transplantation primarily CMV, other herpesviruses, and community acquired respiratory virus infections most recently SARS-CoV-2 currently chairing the EBMT COVID-19 Task Force. Another research area where Per Ljungman has been very active is in vaccination of stem cell transplant patients. He has performed several clinical trials as principal investigator both regarding antivirals and vaccines.

### Keynote Lecture

#### Genomic surveillance for AMR: supporting public health interventions against typhoid and *Klebsiella pneumoniae*

##### *Kathryn Holt (London, United Kingdom)*



Kat is a computational biologist specialising in infectious disease genomics. She is Professor of Microbial Systems Genomics, and co-Director of the Antimicrobial Resistance (AMR) Centre, at London School of Hygiene and Tropical Medicine. Kat holds a BA/BSc, Master of Epidemiology, and PhD in Molecular Biology. Kat and her team are particularly interested in the evolution and spread of AMR, and vaccine design and deployment against AMR pathogens. Two organisms of particular focus are *Salmonella* Typhi (the agent of typhoid fever), and *Klebsiella pneumoniae* (a leading cause of neonatal sepsis and healthcare-associated infections globally). To support genomics-informed research and surveillance for these pathogens, Kathryn's team have developed organism-specific genomic typing tools (Kleborate and Kaptive for *Klebsiella*, GenoTyphi for Typhi), and cofounded international collaborative consortia (KlebNET, and the Global Typhoid Genomics Consortium).

Co-organised with: ESCMID Study Group for Epidemiological Markers (ESGEM)

### Keynote Scientific Interview

#### The syndemic of HIV and STIs

##### *Jeanne Marrazzo (Bethesda, United States)*



Dr. Marrazzo is the Director of the National Institute of Allergy and Infectious Diseases at the U.S. National Institutes of Health (NIH), where she oversees a \$6.3 billion budget that supports research to advance understanding, diagnosis, and treatment of infectious, immunologic, and allergic diseases. She was previously the C. Glenn Cobbs Endowed Chair and Director of Infectious Diseases at the University of Alabama at Birmingham Heersink School of Medicine. She is a Fellow of the American College of Physicians and the Infectious Diseases Society of America (IDSA), and was Treasurer of the IDSA from 2021-2023, having served on the board since 2018. Dr. Marrazzo researches the vaginal microbiome, sexually transmitted infections, and HIV pre-exposure prophylaxis. She has had leadership roles in the NIH HIV Prevention Trials Network and the Infectious Diseases Clinical Research Consortium. She has been a leading voice in communicating science during the COVID-19 pandemic.

Photo credit: NIH/Chia-Chi Charlie Chang

Co-organised with: Infectious Diseases Society of America (IDSA)

# Preliminary Programme

## Keynote Lectures

### Keynote Lecture

#### The role of trained Innate Immunity in infections



#### *Mihai Netea (Nijmegen, Netherlands)*

Mihai Netea studied medicine in Cluj-Napoca, Romania. He completed his PhD at the Radboud University Nijmegen, The Netherlands, on stud Mihai Netea studied medicine in Cluj-Napoca, Romania. He completed his PhD at the Radboud University Nijmegen, The Netherlands, on studies investigating the cytokine network in sepsis. After working as a post-doc at the University of Colorado, he returned to Nijmegen where he finished his clinical training as an infectious diseases specialist, and where he currently heads the division of Experimental Medicine, Department of Internal Medicine, Nijmegen University Nijmegen Medical Center. He is mainly interested in understanding the memory traits of innate immunity (trained immunity), the factors influencing variability of human immune responses, and the immune dysregulation during bacterial and fungal infections. He is the recipient of the Spinoza Prize 2016 and an ERC Advanced grant in 2019, and since 2016 he is a member of the Netherlands Royal Academy of Sciences (KNAW).

Co-organised with: UEMS Section of Infectious Diseases

### Keynote Lecture

#### Innovations in diagnosis, treatment and prevention of malaria



#### *Sodiomon B. Sirima (Ouagadougou, Burkina Faso)*

Sodiomon Bienvenu Sirima, is an expert on clinical trials and is one of the African pioneer in ICH-GCP implemented Malaria vaccine trials. He is holding a Doctorate in Medicine and Surgery (MD), a Bachelor Socio-anthropology (BA) and a PhD in epidemiology. Since 2016 Dr Sirima is the scientific Director of the Groupe de Recherche Action en Santé, Ouagadougou, in Burkina Faso, an independent, local, non-governmental research center founded in 2008 an actively partnering with the Ministry of Health and Ministry of Science and Technology of Burkina Faso. During these last 25 years Sodiomon B. Sirima has led more than thirty epidemiological and community-based studies and more than fifteen ICH-GCP compliant clinical trials. These studies have led to a significant policy changes in malaria control strategies. At Burkina Faso level, he is one of the key opinion leaders in the malaria field. Current research projects include Typhoid, Schistosomiasis, shigella and malaria vaccines and, drug clinical trials.

## Keynote Lecture

### New frontiers in microbiome and human health

#### *Nicola Segata (Trento, Italy)*



Nicola Segata, Ph.D., is Professor and Principal Investigator at the CIBIO Department of the University of Trento (Italy) and Principal Investigator at the European Institute of Oncology in Milan (Italy). He earned his Ph.D. in Computer Science at University of Trento in 2009 and he then moved to Harvard School of Public Health for his post-doctoral training where he started studying the human microbiome with computational metagenomics approaches in the Laboratory of Prof. Curtis Huttenhower. He came back to University of Trento (Department CIBIO) where he started his laboratory in 2013 which employs experimental meta'omic tools and novel computational approaches to study the diversity of the human microbiome across conditions and populations and its role in human diseases. His work is supported by the European Research Council and by several other European agencies. The projects in his laboratory bring together computer scientists, microbiologists, statisticians, and clinicians and focus on profiling microbiomes with strain-level resolution and on meta-analysing very large sets of metagenomes with novel computational tools.

## Keynote Lecture

### Redefining sepsis: past and future

#### *Mervyn Singer (London, United Kingdom)*



Professor of Intensive Care Medicine at University College London, UK. Published mainly on sepsis and multi-organ failure, infection, shock, monitoring. Developed various monitoring and support devices and has two 'home-made' drugs and two devices in current development. Co-chaired Sepsis-3 Definitions International Task Force and past-Chair, International Sepsis Forum. Sepsis Topic Advisor to NICE. Written various textbooks e.g. Oxford Handbook of Critical Care. Has run Medical Emergencies Courses for >25 years. Emeritus NIHR Senior Investigator. Loves being iconoclastic and gently provocative.

## Keynote Lecture

### Emergence of group A streptococcal diseases: from Strep throat to invasive infections

#### *Shiranee Sriskandan (London, United Kingdom)*



Shiranee Sriskandan is Professor of Infectious Diseases at Imperial College London and a Clinical Infectious Diseases consultant at Hammersmith and St Mary's Hospitals. She leads the Gram-Positive Pathogenesis research group within the Department of Infectious Disease, and is clinical director of Imperial's new Centre for Bacteriology Resistance Biology. Her group works on the mechanisms that allow *Streptococcus pyogenes* to cause extreme clinical phenotypes in individuals and populations. The group's work ranges from pathogen virulence to host immune response and vaccines, and relies heavily on collaboration with colleagues in the UK and abroad.

## Keynote Scientific Interview

### A journey from microbiology to infection prevention and control in the era of AMR

#### *Margreet Vos (Rotterdam, Netherlands)*



Prof Dr Margreet C. Vos is a Clinical Microbiologist and since 2012, she is a professor of Healthcare related Infections at the ErasmusMC, Rotterdam, the Netherlands. Her main interests are infection prevention, in particular MSSA/MRSA, the Search and Destroy strategy, hand hygiene, outbreaks, transmission, innate environment, hospital environment and hospital design and endoscope related contamination and infections. She initiated and chaired for many years a national working group (HIP) as part of the Dutch Society of Medical Microbiology (NVMM) and initiated, developed and chaired the committee on infection control national guideline on the organization and quality of hospital infection prevention and developed audits for quality of hospital infection prevention. She was the project-leader of an international (UK FR NL) JPI MACOTRA consortium on (un)success of MRSA clones. She is the scientific officer of ESGNI and chair of the MRSA-ISAC working group.

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee

# Preliminary Programme

## 2-hour Symposia

---

### 2-hour Symposium

#### Elimination of viral hepatitis: a puzzle still to be solved

**Viral hepatitis elimination in 2024: have we moved forward?**

*Erika Duffell (Stockholm, Sweden)*

**Use of simplified approaches for screening and diagnosis of HCV, HBV and HDV infections**

*Simona Ruta (Bucharest, Romania)*

**The best we can do with the treatments we have: is it enough to eliminate HCV, HBV, HDV?**

*Adriana Vince (Zagreb, Croatia)*

**Hepatitis E in vulnerable populations**

*Zeinab Nabil (Cairo, Egypt)*

Co-organised with: Croatian Society for Infectious Diseases of the Croatian Medical Association, ESCMID Study Group for Viral Hepatitis (ESGVH), Società Italiana di Malattie Infettive e Tropicali (SIMIT), Slovenian Society of Infectious Diseases, GEHEP-SEIMC (Study Group of Viral Hepatitis of the Spanish Society of Infectious Diseases and Clinical Microbiology)

---

### 2-hour Symposium

#### Preventing HIV: what more do we need?

**Risk and benefits of breastfeeding in HIV-infected women receiving antiretroviral therapy**

*Angela Colbers (Nijmegen, Netherlands)*

**Novel and enhanced HIV-1 prevention strategies using broadly neutralising antibodies**

*Phillipp Schommers (Cologne, Germany)*

**Use of long-acting cART injectables for prevention of HIV infection**

*TBA*

**Gender inequalities in HIV prevention**

*TBA*

Co-organised with: ESCMID International Affairs, Pan-American Association Infectious Diseases (API)

---

### 2-hour Symposium

#### A new kid on the block: the promises and challenges of molecular wastewater surveillance

**Wastewater surveillance for public health: opportunities and pitfalls**

*Steen Ethelberg (Copenhagen, Denmark)*

**Epidemiological surveillance using waste water**

*Nicholas Grassly (London, United Kingdom)*

**Wastewater surveillance: ethical and legal aspects**

*Michelle M. Mello (Stanford, United States)*

**Wastewater surveillance in Africa: perspective for LMICs**

*Tafadzwa Dzinamarira (Lusaka, Zambia)*

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Epidemiological Markers (ESGEM), ESCMID Study Group for Public Health Microbiology (ESGPHM)

---

### 2-hour Symposium

#### Measles and polio eradication: where do we stand?

**Current epidemiology of measles**

*Patrick O'Connor (Geneva, Switzerland)*

**Global measles eradication: how and when?**

*Hanna Nohynek (Helsinki, Finland)*

**Why is polio still a concern?**

*Thea Kølsten Fischer (Copenhagen, Denmark)*

**Vaccine-derived poliovirus outbreaks - new vaccine and enhanced surveillance**

*Cara Burns (Atlanta, United States)*

Co-organised with: ESCMID Vaccine Study Group (EVASG)

---

### 2-hour Symposium

#### Endocarditis – new guidelines, approaches, and challenges

**The 2023 ESC endocarditis guidelines – what's different?**

*TBA*

**Endocarditis in low- and middle-income countries**

*TBA*

**The battle against IE in the elderly: challenges and treatment options**

*Martha Kestler Hernandez  
(Madrid, Spain)*

**Dental procedures and antibiotic prevention of infective endocarditis: what's new**

*Bruno Hoen (Paris, France)*

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), Sociedad Española de Infecciones Cardiovasculares (SEICAV)

---

### 2-hour Symposium

#### New diagnostic and treatment interventions for tuberculosis based on the immune response

**New perspectives on molecular endotyping that can improve patient stratification and guide clinical management**

*Andrew Di Nardo (Houston, United States)*

**Discovery of immune-enhancing therapies that prevent development of drug-resistant tuberculosis**

*Susanna Brighenti (Stockholm, Sweden)*

**Biomarkers for tuberculosis infection: from the host to the pathogen**

*Delia Goletti (Rome, Italy)*

**Targeting the innate immune response to improve outcomes in TB**

*Jon S. Friedland*

*(London, United Kingdom)*

---

### 2-hour Symposium

#### Sepsis 2024: embracing transformative medicine in the daily practice

**ISF awardee and ESGBIES Young Investigator**

*TBA*

**Precision medicine in sepsis: the time is now!**

*Chaz Langelier  
(San Francisco, United States)*

**Evaluation of long-term sepsis sequelae**

*Carolin Fleischmann-Struzek  
(Jena, Germany)*

**Sepsis: year in review**

*Joost Wiersinga  
(Amsterdam, Netherlands)*

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), European Sepsis Alliance (ESA), International Sepsis Forum (ISF)

---

### 2-hour Symposium

#### Streptococcal infection: from invasive infection to post-infectious sequelae

**Group A *Streptococcus*:**

**burden of disease**

*Pierre Smeesters (Brussels, Belgium)*

***Streptococcus dysgalactiae* subsp. *equisimilis*: an emerging cause of invasive infections**

*Oddvar Oppegaard (Bønes, Norway)*

**Invasive group A and B streptococcal infections in women and children**

*Anna Seale (London, United Kingdom)*

**Post-streptococcal sequelae: acute rheumatic fever and rheumatic heart disease**

*Liesl Zühlke (Cape Town, South Africa)*

# Preliminary Programme

## 2-hour Symposia

### 2-hour Symposium

#### **Staphylococcus aureus bacteraemia: emerging guidelines and updates**

**Defining at-risk populations and treatment duration**

*Achim Kaasch (Magdeburg, Germany)*

**Diagnostic evaluation of SAB**

*Catherine Liu (Seattle, United States)*

**The use of adjuvant treatments in SAB**

*Anna Goodman*

*(London, United Kingdom)*

**Management of MRSA**

*Mical Paul (Haifa, Israel)*

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

### 2-hour Symposium

#### **Plasticity of bacterial genomes: the wonders of horizontal gene transfer**

**Mobile genetic elements in bacteria: not only plasmids and transposons**

*Sally Partridge (Westmead, Australia)*

**Horizontal gene transfer and its role in antibiotic resistance spread**

*Monika Dolejska (Brno, Czech Republic)*

**Plasmidome-microbiome interactions**

*TBA*

**Challenges of tracing mobile genetic elements with whole genome sequencing**

*Henrik Hasman (Copenhagen, Denmark)*

### 2-hour Symposium

#### **Introduction of newer antibiotics in LMICs**

**Access to reserve antibiotics in LMICs**

*Jennifer Cohn (Geneva, Switzerland)*

**Newer antibiotics in the absence of diagnostic capacity: how to balance access and stewardship?**

*Céline Pulcini (Nancy, France)*

**Equitable distribution of antibiotics in LMICs**

*Mirfin Mpundu (Lusaku, Zambia)*

**Developing a national stewardship programme in South Africa**

*Marc Mendelson*

*(Cape Town, South Africa)*

Co-organised with: Global Antibiotic Research and Development Partnership (GARDP)

### 2-hour Symposium

#### **Research agenda in One Health**

**One Health priority research agenda for AMR**

*Haileyesus Getahun*

*(Geneva, Switzerland)*

**Translating research priorities into action for human health**

*Adrian John Brink*

*(Cape Town, South Africa)*

**Estimating the economic burden and return on investment of AMR in environment**

*Chantal Morel (Bern, Switzerland)*

**Innovations in antibacterial development: WHO research and development pipeline**

*Valeria Gigante (Geneva, Switzerland)*

Co-organised with: World Health Organisation (WHO)

### 2-hour Symposium

#### **Providing access to laboratory diagnosis and surveillance in remote settings - problems and solutions**

**The value of global access to diagnostics**

*Yenew Kebede Tebeje*

*(Addis Abbaba, Ethiopia)*

**The Mini-Lab: accessible clinical bacteriology at the district level**

*Alessandra Natale (Paris, France)*

**Rapidly deployable medical mobile lab for epidemic control**

*TBA*

**The Suitcase Lab: real-time, portable genome sequencing for outbreak surveillance**

*Sophie Duraffour (Hamburg, Germany)*

Co-organised with: ESCMID Study Group for Public Health Microbiology (ESGPHM), ESCMID Study Group for Veterinary Microbiology (ESGVM)

---

## 2-hour Symposium

### Moving phage therapy forward: from susceptibility testing to regulatory frameworks

**Clinical phage microbiology: what does it mean?**

*Ronen Hazan (Jerusalem, Israel)*

**Standardising bacteriophage susceptibility testing: a long and winding road?**

*Maria del Mar Tomas (A Coruña, Spain)*

**Key variables in clinical research to assess efficacy of phage therapy**

*Shawna McCallin (Zurich, Switzerland)*

**Bacteriophages: it's a medicine, but not as we know it**

*Jean-Paul Pirnay (Brussels, Belgium)*

Co-organised with: ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)

---

## 2-hour Symposium

### Beyond the label: treatment optimisation in special patient groups

**Tiny patients, big decisions: navigating the challenges and opportunities of personalised antibiotic therapy in children**

*Tuuli Metsvaht (Tartu, Estonia)*

**Treating obese patients: emerging solutions**

*Amit Pai (Ann Arbor, United States)*

**Age ain't just a number: deciphering the altered PK/PD of antibiotics in older patients**

*Pieter De Cock (Gent, Belgium)*

**Administration of antibiotics to elderly – can we make it more elegantly?**

*Claire Roubaud-Baudron*

*(Bordeaux, France)*

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Infections in the Elderly (ESGIE)

---

## 2-hour Symposium

### New strategies to treat infectious diseases

**Innovative genetic engineering strategies to achieve antibacterial activity**

*Sarah Bigot (Lyon, France)*

**Natural antimicrobial peptides and their synthetic derivatives as an alternative to conventional antibiotics**

*Cagla Bozkurt Güzel (Istanbul, Turkey)*

**Monoclonal antibodies to treat infections**

*Bettina Fries (New York, United States)*

**How to improve sequential antibiotic therapy using evolutionary principles**

*Hinrich Schulenburg (Kiel, Germany)*

Co-organised with: Deutsche Gesellschaft für Hygiene und Mikrobiologie, ESCMID Scientific Affairs Subcommittee

---

## 2-hour Symposium

### Antimicrobial stewardship accreditation programmes around the world

**Antimicrobial stewardship accreditation in Africa**

*Isabelle Mweenda*

*(Aberdeen, United Kingdom)*

**Antimicrobial stewardship accreditation in India**

*Anup Warriar (Kochi, India)*

**Antimicrobial stewardship accreditation in Australia**

*Karin Thursky (Karlton, Australia)*

**Antimicrobial stewardship accreditation in Spain**

*Antonio Lopez (Madrid, Spain)*

Co-organised with: British Society for Antimicrobial Chemotherapy (BSAC)

# Preliminary Programme

## 2-hour Symposia

---

### 2-hour Symposium

#### Fungal infections from a One Health perspective

Lesson learned from the animal kingdom  
*TBA*

***Candida auris*: current epidemiology and battle plan**  
*Vincenzo Di Pilato (Genoa, Italy)*

***Fusarium* outbreaks – expect the unexpected**  
*Fernanda Gonzalez (Mexico City, Mexico)*

**Fungal outbreaks on the horizon of climate change**  
*Dee Carter (Sydney, Australia)*

Co-organised with: ESCMID Fungal Infection Study Group (EFISG)

---

### 2-hour Symposium

#### Controversies and challenges in antifungal therapy

Reassessment of antifungal combination therapies: misuse versus rational indications  
*Monica Slavin (Melbourne, Australia)*

Therapeutic drug monitoring: current indications and practical implementation of individualised dosing  
*Russel Lewis (Treviso, Italy)*

Individualised dosing in the ICU: weight, third space, albumin, replacement therapies and other conundrums  
*Roger Brüggemann (Nijmegen, Netherlands)*

New antifungal agents: latest developments and future perspectives  
*Martin Hoenigl (Graz, Austria)*

Co-organised with: ESCMID Fungal Infection Study Group (EFISG), ESCMID Study Group for Infections in Compromised Hosts (ESGICH), Society of Infectious Diseases Pharmacists (SIDP)

---

### 2-hour Symposium

#### Climate change and the spectrum of infectious consequences

Ancient viruses revived from permafrost  
*Jean-Michel Claverie (Marseille, France)*

Monitoring the effects of climate change on the distribution of infectious diseases  
*Rachel Lowe (Barcelona, Spain)*

Climate change and AMR: challenges in a moving world  
*Sabiha Essack (Durban, South Africa)*

Climate change and cholera  
*TBA*

Co-organised with: Deutsche Gesellschaft für Infektiologie, ESCMID Professional Affairs Subcommittee, ESCMID Study Group for Infections in Travellers and Migrants (ESGITM), Trainee Association of ESCMID (TAE) Steering Committee

---

### 2-hour Symposium

#### Bacterial pathogens across One Health: a genomic view

Pathogenesis of human leptospirosis  
*TBA*

Dissemination of *Burkholderia pseudomallei* in endemic and non-endemic settings  
*Bart Currie (Casuarina, Australia)*

The genomic epidemiology of *Brucella melitensis* in humans and animal husbandries  
*Jacob Moran-Gilad (Beer Sheva, Israel)*

Invasiveness and resistance of *Salmonella* in low resource countries  
*Sandra van Puyvelde (Wilrijk, Belgium)*

---

### 2-hour Symposium

#### New approaches for malaria screening, management and prevention

**Screening for imported malaria: who, how and why?**

*Anna Färnert (Stockholm, Sweden)*

**Management of malaria cases in the era of drug resistance**

*Phillippe Guerin (Oxford, United Kingdom)*

**Best practices for prevention of malaria transmission during transfusion and transplantations**

*Francesca Norman (Madrid, Spain)*

**Malaria prophylaxis – new recommendations and alternative dose schedule**

*Eli Schwartz (Ramat Gan, Israel)*

Co-organised with: ESCMID Study Group for Infections in Travellers and Migrants (ESGITM), ESCMID Professional Affairs Subcommittee, ESCMID Study Group for Clinical Parasitology (ESGCP), ESCMID Study Group for Infections in Compromised Hosts (ESGICH)

---

### 2-hour Symposium

#### Design does matter: Prevention through creating a microbe-safe hospital

**The microbe-safe hospital: the role of design to optimise safety**

*TBA*

**Architectural design strategies for infection prevention and control in healthcare facilities: prepare for the future**

*TBA*

**Water and surfaces: where is the risk and how to prevent it**

*Hilary Humphreys (Dublin, Ireland)*

**Optimising healthcare ventilation**

*Catherine Noakes*

*(Leeds, United Kingdom)*

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI)

---

### 2-hour Symposium

#### The microbiome and gut-brain axis in neurological diseases

**The role of the gut microbiome in Alzheimer's disease**

*Giovanni Frisoni (Geneva, Switzerland)*

**The role of the gut microbiome in Parkinson's disease**

*Fiorella Contarino (Leiden, Netherlands)*

**The role of the gut microbiome in multiple sclerosis: potential for treatment?**

*Anne-Katrin Pröbstel (Basel, Switzerland)*

**The role of the gut microbiome in cerebrovascular disease**

*Bastiaan Haak (Amsterdam, Netherlands)*

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI), ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

---

### 2-hour Symposium

#### Covert pathogenesis: unexpected impact of co-occurring organisms during polymicrobial infection

**Cooperation and competition in the human nasal microbiota**

*Silvio Brugger (Zurich, Switzerland)*

**Co-ascending vaginal microbes during in utero infection**

*Katy Patras (Houston, United States)*

**Polymicrobial interactions in UTI**

*Marjon de Vos (Groningen, Netherlands)*

**Fungal-bacterial interactions in infections**

*Ilse Jacobsen (Jena, Germany)*

---

### 2-hour Symposium

#### Translating fundamental science for treating biofilm infections

**People are not petri plates: why antibiotics fail in biofilm infection treatment**

*Thomas Bjarnsholt*

*(Copenhagen, Denmark)*

**Microengineered models to study biofilm-associated urinary tract infections**

*John McKinney (Lausanne, Switzerland)*

**Antibiofilm peptides: overcoming biofilm-related treatment failure**

*Robert E.W. Hancock (Vancouver, Canada)*

**Nano-approaches to target biofilm infections**

*Rikke Louise Meyer (Aarhus, Denmark)*

# Preliminary Programme

## 2-hour Symposia | 1-hour Symposia

---

### 2-hour Symposium

#### Treatment strategies for transplant-associated infections

**Adenovirus in stem-cell transplant recipients**

*Thomas Lion (Vienna, Austria)*

**CMV infection in the transplant setting**

*Atul Humar (Toronto, Canada)*

**BK virus in renal transplant - clinical management and development**

*Gabriel Westman (Uppsala, Sweden)*

**Burden and management of multidrug-resistant infections in SOT recipients**

*Maddalena Giannella (Bologna, Italy)*

---

### 2-hour Symposium

#### The future of infection treatment and prevention in the immunocompromised

**Biologicals and infection: a heterogeneous risk profile**

*Isabel Ruiz-Camps (Barcelona, Spain)*

**Cellular therapies for immunocompromised difficult-to-treat infections**

*Nina Khanna (Basel, Switzerland)*

**CAR-T complications: what does an ID specialist need to know?**

*Carlota Gudiol (Barcelona, Spain)*

**Xenotransplantation suddenly a reality: and xeno-zoonoses?**

*Kapil K. Saharia (Baltimore, United States)*

Co-organised with: International Immunocompromised Host Society (ICHS)

---

---

### 2-hour Symposium

#### Making teaching work: from classical lectures to eLearning and beyond

**Effective and engaging teaching: is eLearning the solution?**

*Jo Hart (Manchester, United Kingdom)*

**Bedside/benchside teaching and simulation: just entertaining or improving the outcomes?**

*Nathan Pfeiffer-Smadja (Paris, France)*

**Serious games design: tackling challenges and measuring educational impact**

*Nienke Beerlage-de Jong*

*(Enschede, Netherlands)*

**How to produce impactful educational content on social media**

*Erin Bonura (Portland, United States)*

Co-organised with: ESCMID Education Subcommittee, International Federation of Medical Students Associations (IFMSA)

---

### 2-hour Symposium

#### Risk communication: lessons learnt and best practices for the next pandemic

**TBA**

*Kai Kupferschmidt (Berlin, Germany)*

**Scientific communication to the public during medical emergency**

*Siouxsie Wiles (Auckland, New Zealand)*

**Communicating public health policy during medical emergency**

*Benjamin Djoudalbaye*

*(Addis Ababa, Ethiopia)*

**TBA**

*Helen Branswell (New York, United States)*

---

### 1-hour Symposium

#### Prevention of transfusion-associated infections

**The challenge of occult HBV infected donors**

*William Irving  
(Nottingham, United Kingdom)*

**Preventing transfusion-associated malaria in Europe**

*Sophie Le Cam (Paris, France)*

Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), European Society for Clinical Virology (ESCV)

---

### 1-hour Symposium

#### Seasonal influenza, COVID-19 and RSV: where do we go?

**Epidemiology and surveillance**

*Colin Russell (Amsterdam, Netherlands)*

**Laboratory-based and point-of-care diagnosis**

*Sylvie van der Werf (Paris, France)*

Co-organised with: European Scientific Working group on Influenza (ESWI)

---

### 1-hour Symposium

#### Long COVID: from mechanism of injury to treatment

**Mechanisms of post-COVID syndrome and therapeutic strategies**

*Carmen Scheibenbogen  
(Berlin, Germany)*

**Update on recent developments in treatment of Long COVID**

*TBA*

Co-organised with: European Medicines Agency (EMA), Collaborative on Fatigue Following Infection (COFFI)

---

### 1-hour Symposium

#### Changing epidemiology of West Nile Virus infections in Europe

**West Nile virus surveillance in humans**

*Flavia Riccardo (Rome, Italy)*

**West Nile Virus infections: from animals to humans**

*Norbert Nowotny (Vienna, Austria)*

Co-organised with: Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V.

---

---

### 1-hour Symposium

#### Human papillomavirus: should we immunise more than teens?

**Current impact of the HPV vaccine according to vaccine coverage**

*Suzanne Garland (Parkville, Australia)*

**Adults above 25, and those who already experienced an HPV-associated disease: should we extend the target of vaccination?**

*Matthias Jentschke (Hannover, Germany)*

Co-organised with: ESCMID Vaccine Study Group (EVASG)

---

### 1-hour Symposium

#### Chemotherapy and other options for drug-resistant tuberculosis

**What are the chemotherapy options for drug-resistant TB?**

*Young Ae Kang (Seul, Republic of Korea)*

**Search and destroy of latent TB: the best option for drug-resistant TB?**

*Raquel Duarte (Porto, Portugal)*

Co-organised with: Korean Society of Clinical Microbiology (KSCM)

---

### 1-hour Symposium

#### New treatments for CNS infections

**Dexamethasone in herpes encephalitis: are all votes in?**

*Tom Solomon (Liverpool, United Kingdom)*

**Progressive multifocal leukoencephalopathy treated by immune checkpoint inhibitors**

*Guillaume Martin-Blondel  
(Toulouse, France)*

Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

---

# Preliminary Programme

## 1-hour Symposia

---

### 1-hour Symposium

#### Anaerobic bloodstream infections - diagnostic and treatment strategies

Diagnostic methods and resistance detection in anaerobic BSI  
*Ulrik S. Justesen (Odense, Denmark)*

Clinical relevance and treatment strategies of anaerobic BSI  
*Roberta Maria Antonello (Florence, Italy)*

Co-organised with: ESCMID Study Group for Anaerobic Infections (ESGAI)

---

### 1-hour Symposium

#### Convergent hypervirulence and multi-drug resistance in *Klebsiella pneumoniae*: the worst nightmare

Risk factors and clinical impact of hypervirulent multidrug-resistant *Klebsiella pneumoniae*  
*Şiran Keske (Istanbul, Turkey)*

When to suspect hypervirulent *Klebsiella pneumoniae*: the role of laboratory diagnostics  
*Andrea Endimiani (Bern, Switzerland)*

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

---

### 1-hour Symposium

#### Using evolutionary principles to fight antimicrobial resistance

Tackling tolerance to avoid antibiotic resistance development  
*Nathalie Questembert-Balaban (Jerusalem, Israel)*

Evolved collateral susceptibility as a focus to optimise antibiotic therapy  
*Hinrich Schulenburg (Kiel, Germany)*

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

---

### 1-hour Symposium

#### Carbapenems for treating multidrug-resistant Gram-negative infections: pro/con debate

Pro: carbapenems for patients with resistant micro-organisms  
*Pranita Tamma (Baltimore, United States)*

Con: preserving carbapenems by using alternative antibiotics  
*Heiman Wertheim (Nijmegen, Netherlands)*

Co-organised with: Dutch Committee on Antimicrobial Policy (SWAB), Society of Infectious Diseases Pharmacists (SIDP)

---

### 1-hour Symposium

#### Bacteraemia and antimicrobial resistance surveillance among vulnerable children

Carriage of antimicrobial resistance amongst hospitalised children in Africa  
*Sam Kariuki (Nairobi, Kenya)*

Neonatal bacteraemia and antimicrobial resistance surveillance  
*Phoebe Williams (Sydney, Australia)*

---

### 1-hour Symposium

#### Antimicrobial resistance among displaced populations

Challenges of antimicrobial stewardship in countries with expanding displaced populations in the Middle East  
*Souha S. Kanj (Beirut, Lebanon)*

Ukraine war and antimicrobial resistance challenges  
*Sergii Antoniak (Kiev, Ukraine)*

Co-organised with: ESCMID International Affairs (EIAS)

---

### 1-hour Symposium

#### Single vs. separate venipunctures to draw the same blood volume for diagnosing bacteraemia: pros and cons

Single venipuncture  
*Brigitte Lamy (Nice, France)*

Separate venipunctures  
*Michael L. Wilson (Denver, United States)*

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES)

---

### 1-hour Symposium

#### Diagnostic stewardship: moulding clinician behaviour

**Minding the moulds, advancing diagnostic stewardship in clinical practice**  
*Cornelia Lass-Flörl (Innsbruck, Austria)*

**Empowering junior doctors with diagnostic stewardship principles**  
*Johnny Zakhour (Detroit, United States)*

Co-organised with: International Society of Antimicrobial Chemotherapy (ISAC)

---

### 1-hour Symposium

#### Don't forget the PETs in infection diagnosis and follow up

**PET in Gram-positive bloodstream infection**  
*Nesrin Ghanem-Zoubi (Haifa, Israel)*

**The use of PET in vascular graft infection**  
*Barbara Hasse (Zurich, Switzerland)*

Co-organised with: ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

---

### 1-hour Symposium

#### Decoding plasmids in diagnostics and infection control

**Bacterial plasmid typing: state of the art**  
*Alessandra Carattoli (Rome, Italy)*

**Making sense of plasmid-borne transmission of AMR**  
*Teresa M. Coque (Madrid, Spain)*

Co-organised with: ESCMID Emerging Infections Task Force (EITaF) chair, ESCMID Study Group for Lyme Borreliosis (ESGBOR)

---

### 1-hour Symposium

#### Emerging pathogens from the forensic perspective

**Emerging and common human cardiotropic viruses as causes of sudden cardiac death**  
*Laurent Andreoletti (Reims, France)*

**Moulds in the home environment: from allergies to sudden deaths in young children**  
*Jean-Pierre Gangneux (Rennes, France)*

Co-organised with: ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR), European Network of Forensic Sciences Institutions (ENFSI)

---

---

### 1-hour Symposium

#### Top papers in antimicrobial pharmacology

**The pharmacologist's selection**  
*Erwin Dreesen (Leuven, Belgium)*

**The pharmacometrician's selection**  
*Brenda de Winter (Rotterdam, Netherlands)*

---

### 1-hour Symposium

#### Use of AI in antibiotic discovery and treatment adaptation

**Antibiotic discovery with machine learning**  
*Jonathan Stokes (Hamilton, Canada)*

**A machine learning approach coupled with population PK for optimisation of anti-infectious treatments**  
*Jean Baptiste Woillard (Limoges, France)*

---

### 1-hour Symposium

#### Behavioural insights and community engagement to influence appropriate antibiotic use

**Using the WHO Tailoring Antimicrobial Resistance Programmes (TAP)**  
*Ketevan Kandelaki (Copenhagen, Denmark)*

**Responsive dialogue toolkit for community engagement on AMR**  
*Renier Coetzee (Cape Town, South Africa)*

---

### 1-hour Symposium

#### Detection and control of rare fungal outbreaks

**Rare yeast outbreaks and prevention strategies**  
*Silke Schelenz (London, United Kingdom)*

**Rare mould outbreaks and control strategies in healthcare and community settings**  
*Tom Chiller (Atlanta, United States)*

---

# Preliminary Programme

## 1-hour Symposia

---

### 1-hour Symposium

#### ***Pneumocystis jirovecii* pneumonia: diagnostic updates**

*Pneumocystis jirovecii* pneumonia in the ICU patient

*Daniele Giacobbe (Genoa, Italy)*

Strengths and limitations of *Pneumocystis jirovecii* pneumonia molecular diagnostics

*Riina Richardson*

*(Manchester, United Kingdom)*

Co-organised with: ESCMID Fungal Infection Study Group (EFISG)

---

### 1-hour Symposium

#### **Tropical diseases: management dilemmas and newer concepts**

Management dilemmas in cysticercosis

*Hector H. Garcia (Lima, Peru)*

Dengue - newer antivirals and host modulating therapies

*Neelika Malavige (Colombo, Sri Lanka)*

---

### 1-hour Symposium

#### **NTDs with skin manifestations: Diagnostic and treatment challenges**

Cutaneous leishmaniasis

*TBA*

NTMs: Buruli ulcer and Hansen's disease

*Pedro Legua (Lima, Peru)*

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP), ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)

---

### 1-hour Symposium

#### **Top papers in tropical medicine and clinical parasitology**

Top papers in tropical medicine

*Martin Montes (Lima, Peru)*

Top papers in clinical parasitology

*Priscilla Rupali (Vellore, India)*

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)

---

### 1-hour Symposium

#### **Health and hygiene in maternal and neonatal units across the world**

Infection prevention and control in maternity and neonatal units in low-and middle-income countries

*TBA*

Infection prevention in the neonatal intensive care unit in high income countries – the neonatologists perspective

*Angelika Berger (Vienna, Austria)*

Co-organised with: European Society of Paediatric Infectious Diseases (ESPID)

---

### 1-hour Symposium

#### **Healthcare-associated infections: data for action and prevention standards to improve patient safety**

Infection prevention and control standards and safe workflows for patients with special medical conditions

*Sarah Tschudin-Sutter (Basel, Switzerland)*

Healthcare-associated infections in Europe in the aftermath of the COVID-19 pandemic: results of the 3rd ECDC PPS

*Carl Suetens (Stockholm, Sweden)*

---

### 1-hour Symposium

#### **Screening for the control of multidrug-resistant organisms in hospitals: adapting strategies to cross-border care needs**

Epidemiology of cross-border transmission of multidrug-resistant organisms to hospitals in Europe

*Mikael Kajova (Helsinki, Finland)*

MDRO admission screening for cross-border hospital care

*TBA*

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), ESCMID Study Group for Public Health Microbiology (ESGPHM)

---

### 1-hour Symposium

#### Automated surveillance of bloodstream infections

Multinational electronic surveillance systems for bloodstream infections in EU/EEA  
*Diamantis Plachouras (Solna, Sweden)*

Automated surveillance of healthcare-associated infections  
*Maaïke van Mourik (Zeist, Netherlands)*

Co-organised with: European Centre for Disease Prevention and Control (ECDC)

---

### 1-hour Symposium

#### Antibiotic hetero-resistance: does it matter?

Single cell imaging for antibiotic susceptibility testing  
*Johan Elf (Uppsala, Sweden)*

Therapeutic approaches to combat hetero-resistance in Gram-negative pathogens  
*David Weiss (Atlanta, United States)*

Co-organised with: ESCMID Scientific Affairs Subcommittee

---

### 1-hour Symposium

#### Bacteriophage therapeutics for biofilm infections: hopes and hurdles

Bacteriophages for difficult-to-treat infections: a clinical perspective  
*Christian Van Delden (Geneva, Switzerland)*

Strategies to improve phage therapy against chronic infections  
*Joana Azeredo (Braga, Portugal)*

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)

---

### 1-hour Symposium

#### Biofilms and *Clostridioides difficile* infection recurrence

Building of biofilm, a metabolic reprogramming  
*Bruno Dupuy (Paris, France)*

Biofilm and *Clostridioides difficile* infection recurrences  
*Ines Moura (Leeds, United Kingdom)*

Co-organised with: ESCMID Study Group for *Clostridioides difficile* (ESGCD)

---

### 1-hour Symposium

#### Tough nuts to crack: the challenges and future of VRE infection and treatment

Immunomodulatory approaches to treating VRE infection  
*Kimberly Kline (Geneva, Switzerland)*

Combinatorial treatment strategies for VRE  
*Josè M. Miro (Barcelona, Spain)*

---

### 1-hour Symposium

#### Neuroimmune-modulation in infections: from pathogenic mechanisms to novel adjunct therapies

Bacteria hijack the neuroimmune axis for bacterial invasion  
*TBA*

Understanding inflammation through neuroscience  
*Peder Olofsson (Stockholm, Sweden)*

---

### 1-hour Symposium

#### Vaccine preventable diseases in the immunocompromised host: new developments

Strategies to enhance vaccination uptake in immunocompromised patients  
*Ben Teh (Melbourne, Australia)*

The role of monoclonal antibodies in preventing infection  
*Natasha Halassa (Nashville, United States)*

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH)

---

### 1-hour Symposium

#### Top papers in immunocompromised infectious diseases

Top papers in SOT ID  
*Hans Hirsch (Basel, Switzerland)*

Top papers in HSCT/primary immunodeficiency ID  
*Clarisse Machado (Sao Paulo, Brazil)*

# Preliminary Programme

## 1-hour Symposia | Meet-the-Expert

---

### 1-hour Symposium

#### Which randomised controlled trial do we need?

**Missing evidence: clinical trials in life-threatening infectious diseases**  
*Guy Thwaites (Ho Chi Minh City, Viet Nam)*

**Clinical trial design and data collection**  
*Lauren Maxwell (Heidelberg, Germany)*

Co-organised with: CMI Board of Editors, European Clinical Research Alliance on Infectious Diseases (ECRAID)

---

### 1-hour Symposium

#### Machine learning and generative AI in CM/ID practice

**Generative AI – applications in CM/ID practice**  
*Chang Ho Yoon (Oxford, United Kingdom)*

**The challenges and limitations of using AI in CM/ID**  
*Catherine Jutzeler (Zurich, Switzerland)*

Co-organised with: Trainee Association of ESCMID (TAE) Steering Committee, ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD)

---

Meet-the-Expert

**RSV control within reach**

*Peter Openshaw  
(London, United Kingdom)*

TBA

---

Meet-the-Expert

**Guidance for influenza treatment**

*Barbara Rath (Besancon, France)*

*Giulia De Angelis (Rome, Italy)*

Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV)

---

Meet-the-Expert

**Post-exposure prevention of STIs with antibiotics: pros and cons**

*Deniz Gokengin (Izmir, Turkey)*

*Jean-Michel Molina (Paris, France)*

Co-organised with: Euroguidelines in Central and Eastern Europe (ECEE) Network Group

---

Meet-the-Expert

**Using antimicrobial susceptibility testing of nontuberculous mycobacteria to improve clinical practice**

*Jakko van Ingen (Nijmegen, Netherlands)*

*Claire Andrejak (Amiens, France)*

Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC)

---

Meet-the-Expert

**How to use follow-up blood cultures in patients with Gram-negative bacteraemia**

*Joshua Thaden (Durham, United States)*

*Mo Yin (Singapore, Singapore)*

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES)

---

Meet-the-Expert

**Treatment of infective endocarditis: back to the future**

*Mia Marie Pries-Heje  
(Copenhagen, Denmark)*

*Eugene Athan (Geelong, Australia)*

---

Meet-the-Expert

**How to use CRISPR-Cas to combat AMR**

*Kelli Palmer (United States)*

*Peter Fineran (Dunedin, New Zealand)*

---

Meet-the-Expert

**EUCAST Frequently Asked Questions in AST**

*Erika Matuschek (Växjö, Sweden)*

*Rafael Canton (Madrid, Spain)*

Co-organised with: EUCAST Steering Committee

---

Meet-the-Expert

**Controversies in diagnosis and treatment of difficult Gram-negative infections**

*Veeraraghavan Balaji (Vellore, India)*

*Sasheela Ponnampalavanar  
(Kuala Lumpur, Malaysia)*

---

Meet-the-Expert

**Those who are now named: identifying "difficult" bacteria**

*Belen Rodriguez Sanchez (Madrid, Spain)*

*Alida Veloo (Groningen, Netherlands)*

Co-organised with: ESCMID Study Group for Anaerobic Infections (ESGAI)

---

Meet-the-Expert

**Spitting image: using saliva as a diagnostic sample**

*Rachel Byrne (Liverpool, United Kingdom)*

*Anne Wyllie (New Haven, United States)*

Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV)

# Preliminary Programme

## Meet-the-Expert

---

### Meet-the-Expert

#### The role of local microbiology in a world of high throughput off-site labs

*Robin Patel (Rochester, United States)*

*Patrick Jeurissen  
(Nijmegen, Netherlands)*

---

### Meet-the-Expert

#### The sustainable microlab - how green can we become?

*Jane Kilcoyne (Oranmore, Ireland)*

TBA

---

### Meet-the-Expert

#### The dish of the day: individualised antibiotic dosing in critically ill patients

*Uwe Liebchen (Munich, Germany)*

*Sonya Tang Girdwood  
(Cincinnati, United States)*

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Critically Ill Patients (ESGCIP)

---

### Meet-the-Expert

#### PK/PD modelling: from bench to bedside

*Sebastian Wicha (Hamburg, Germany)*

*Angela Huttner (Geneva, Switzerland)*

---

### Meet-the-Expert

#### Diagnosing fungal infections in clinical practice

*Katrien Lagrou (Leuven, Belgium)*

*Bart Rijnders (Rotterdam, Netherlands)*

Co-organised with: ESCMID Fungal Infection Study Group (EFISG), Société belge infectiologie et de microbiologie clinique (SBIKM)

---

### Meet-the-Expert

#### Emerging strategies for invasive fungal disease management

*Carolina Garcia Vidal (Barcelona, Spain)*

*Anna Khanina (Melbourne, Australia)*

Co-organised with: ESCMID Fungal Infection Study Group (EFISG)

---

### Meet-the-Expert

#### Diagnosis and treatment of rare infections in migrants and travellers

*Watcharapong Piyaphanee  
(Bangkok, Thailand)*

*Adesola Yinka-Ogunleye (Abuja, Nigeria)*

Co-organised with: ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)

---

### Meet-the-Expert

#### Cardiovascular implant infections: current challenges

*Barbara Hasse (Zurich, Switzerland)*

*Alexander Maas (Groningen, Netherlands)*

Co-organised with: ESCMID Study Group for Implant-associated Infections (ESGIAI)

---

### Meet-the-Expert

#### Improving implementation in infection prevention and control

*Gabriel Birgand (Nantes, France)*

*Lauren Clack (Zurich, Switzerland)*

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), Trainee Association of ESCMID (TAE) Steering Committee, EUCIC Steering Committee

---

### Meet-the-Expert

#### Nosocomial infection in the adult patient with ECMO support

*Marta María Hernández  
(Barcelona, Spain)*

*Konstanty Szuldrzyński (Krakow, Poland)*

Co-organised with: EuroELSO

---

---

**Meet-the-Expert**

**When colonisers run amok: how to study carriage of bacteria**

*Carmen Munoz-Almagro  
(Barcelona, Spain)*

*Adam Finn (Bristol, United Kingdom)*

---

**Meet-the-Expert**

**Children are not just small adults: interactive paediatric cases**

*Julie Toubiana (Paris, France)*

*Sanjay Patel  
(Winchester, United Kingdom)*

Co-organised with: European Society of Paediatric Infectious Diseases (ESPID)

---

**Meet-the-Expert**

**When to say yes: selecting organ donors with known infections**

*Ann Wooley (Boston, United States)*

*Alessandra Mularoni (Palermo, Italy)*

---

**Meet-the-Expert**

**Using foresight for disease preparedness and response**

*Gerjon Ikink (Stockholm, Sweden)*

*Klaudia Palczak (Lisbon, Portugal)*

Co-organised with: European Centre for Disease Prevention and Control (ECDC)

# Preliminary Programme

## Educational Sessions

---

### Educational Session

#### Guide to HIV-associated opportunistic infections

Rare and difficult-to-treat HIV-associated opportunistic infections

*Arjan Harxhi (Tirana, Albania)*

Should we diagnose and treat opportunistic infections differently in HIV than in other immunocompromised patients?

*Daria Podlekareva*

*(Copenhagen, Denmark)*

Prophylaxis of opportunistic infections

*Anton Pozniak (London, United Kingdom)*

Are opportunistic infections still a problem in European countries in the ART era?

*Cristiana Oprea (Bucharest, Romania)*

Co-organised with: Euroguidelines in Central and Eastern Europe (ECEE) Network Group, Danish Infectious Disease Society

---

### Educational Session

#### Exotic viral hepatitis: from changing epidemiology to appropriate case management

Rare but deadly - HSV Hepatitis during pregnancy

*TBA*

Diagnosis and prevention of vector-borne hepatitis

*Önder Ergönül (Istanbul, Turkey)*

Flaviviral hepatitis acquired in endemic destinations

*Antonio Bandeira (Salvador, Brazil)*

Viral hepatitis in returning travellers: beyond major hepatotropic viruses

*Karine Lacombe (Paris, France)*

Co-organised with: ESCMID Emerging Infections Task Force (EITaF) chair, ESCMID Study Group for Viral Hepatitis (ESGVH), GeoSentinel, FIGO (The International Federation of Gynecology and Obstetrics), Colombian Association of Infectious Diseases

---

### Educational Session

#### How to deal with urinary tract infections in 2024: from guidelines to practice

The IDSA 2023 guidelines: new definitions and new approaches to 'uncomplicated' and 'complicated' UTI

*Barbara Trautner (Houston, United States)*

The European Urological Association's 2023 guideline: how to deal with prostatitis and other complicated UTIs

*Florian Wagenlehner (Giessen, Germany)*

Short course treatment of UTI: still works?

*Kalpana Gupta (Boston, United States)*

Antibiotic stewardship for UTI in primary care

*Theo Verheij (Utrecht, Netherlands)*

Co-organised with: ESCMID Guidelines Subcommittee

---

### Educational Session

#### Management of lower respiratory tract infections

Cutting edge diagnostics in LRTI

*Kev Dhaliwal (Edinburgh, United Kingdom)*

Colonisation or infection in patient with underlying bronchiectasis

*Eva Polverino (Barcelona, Spain)*

Treatment and telemetric monitoring: towards a virtual ward at home

*Annelies Verbon (Utrecht, Netherlands)*

Health technology assessment of diagnostic strategies

*Alec Morton (London, United Kingdom)*

Co-organised with: Value-Dx

---

### Educational Session

#### Rapid detection of antibiotic resistance – state-of-the-art

**Molecular-based AMR detection:  
still the panacea?**

*Surbhi Malhotra-Kumar  
(Antwerp, Belgium)*

**Non-molecular approaches for wide  
implementation**

*Jaroslav Hrabak (Prague, Czech Republic)*

**How current rapid diagnostic tests can  
support antibiotic stewardship?**

*Evelina Tacconelli (Verona, Italy)*

**Rapid diagnostic for AMR: what would I  
need as a clinician in a perfect world?**

*Florence Ader (Lyon, France)*

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

---

### Educational Session

#### EUCAST Educational Session

**EUCAST Update**

*Christian Giske (Stockholm, Sweden)*

**An update on antifungal susceptibility  
testing and resistance screening**

*Maiken Cavling Arendrup  
(Copenhagen, Denmark)*

**Paediatric dosing**

*Malte Kohns Vasconcelos  
(Hamburg, Germany)*

**Endocarditis breakpoints**

*Christoffer Lindemann (Bergen, Norway)*

**Beta-lactamase/beta-lactamase  
Inhibitors**

*Shampa Das (Liverpool, United Kingdom)*

Co-organised with: European Committee on Antimicrobial Susceptibility Testing (EUCAST)

---

### Educational Session

#### The use of metagenomics in diagnostics and surveillance

**Use of metagenomics to enhance  
diagnosis of encephalitis**

*Judy Breuer (London, United Kingdom)*

**Utility of metagenomics to enhance the  
management of severe respiratory  
infections**

*TBA*

**Combining host response profiling  
with metagenomics: is this the future of  
infectious disease diagnostics?**

*Charles Chiu  
(San Francisco, United States)*

**Routine implementation of metagenomics  
in the clinic - what's next?**

*Nicole Fischer (Hamburg, Germany)*

Co-organised with: European Society for Clinical Virology (ESCV)

---

### Educational Session

#### Empowering young microbiologists: bioinformatic tools for routine workflows

**Why bioinformatics is the future of clinical  
microbiology: impact of data-driven  
approaches**

*Torsten Seeman (Melbourne, Australia)*

**Easy bioinformatics projects as a starting  
point for bigger discoveries**

*Oliver Schwengers (Giessen, Germany)*

**Translating bioinformatics into clinical  
utility**

*Anita Schürch (Utrecht, Netherlands)*

**Building capacity: Investing in a  
bioinformatician or bioinformatic  
software?**

*Helena Seth-Smith (Zurich, Switzerland)*

Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Trainee Association of ESCMID (TAE) Steering Committee

# Preliminary Programme

## Educational Sessions

---

### Educational Session

#### Practical implications of the EU *in vitro* diagnostic medical device regulation for clinical microbiology

The role of EQA/PT providers in post market surveillance according to EU IVDR  
*Christoph Buchta (Vienna, Austria)*

How to interpretate IVDR for culture-based diagnostic methods  
*Peter Vermeersch (Leuven, Belgium)*

Experience from production of in house IVDs according to IVDR  
*Andreas Resar (Umeå, Sweden)*

Into the unknown: formulating society guidelines for interpreting and implementing IVDR in clinical microbiology laboratories  
*Helle Brander Eriksen (Copenhagen, Denmark)*

Co-organised with: Nordic Society of Clinical Microbiology and Infectious Diseases (NSCMID), Biomed Alliance

---

### Educational Session

#### The big cinema of treating infectious diseases: blockbusters and evergreens

The good, the bad and the ugly: the reality behind antibiotics with broad and narrow therapeutic index  
*Maya Hites (Brussels, Belgium)*

Highlander, there can be only one: clinically relevant drug interactions with antimicrobials  
*Markus Zeitlinger (Vienna, Austria)*

Mission impossible? Treatment of deep-seated infections and biofilms  
*Oana Ciofu (Copenhagen, Denmark)*

From dusk till dawn – what is the real value of continuous antibiotic infusion at the ICU?  
*Isabel Spriet (Leuven, Belgium)*

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

---

### Educational Session

#### The alfa and omega of antimicrobial stewardship: optimising antimicrobial therapy at hospital entry and discharge

Optimising antimicrobial therapy in the emergency room: the role of rapid diagnostics  
*Cihan Papan (Bonn, Germany)*

ESCMID guidelines for antimicrobial stewardship at the emergency room  
*Teske Schoffelen (Nijmegen, Netherlands)*

Careful goodbye at the door: antimicrobial stewardship interventions for antimicrobials on hospital discharge  
*Valerie Vaughn (Salt Lake City, United States)*

How to deal with overuse at discharge in a resource limited setting  
*Florence Lieutier-Colas (Strasbourg, France)*

Co-organised with: ESCMID Study Group for Antimicrobial stewardship (ESGAP)

---

### Educational Session

#### Multidisciplinary teams for selecting antimicrobial therapy for bone and joint infections: the key for success

Selection of an appropriate treatment for bone and joint infections in real patients: a puzzle of controversies  
*Joan Gómez (Barcelona, Spain)*

What do we need from a microbiologist? The MIC or the MBIC: new information about PK/PD in biofilms  
*Claus Moser (Copenhagen, Denmark)*

The role of a clinical pharmacist in antibiotic treatment individualisation of special populations  
*Isabel Spriet (Leuven, Belgium)*

Long-term suppressive antimicrobial treatments for BJI: the risk of toxicity and development of resistance  
*Parham Sendi (Bern, Switzerland)*

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

---

### Educational Session

#### Treating CNS infections using modelling approaches: a translational point of view

**Factors determining drug selection for CNS infections**

*Christina König (Hamburg, Germany)*

**Physiologically-based modelling in the study of antibiotic distribution in the CNS**

*Alexia Chauzy (Poitiers, France)*

**Understanding the blood brain barrier, the blood-CSF barrier and beyond**

*Bettina Pfausler (Innsbruck, Austria)*

**PK/PD of antibiotics and antimicrobial resistance in CNS infections: a clinical point of view**

*Gauri Rao (Chapel Hill, United States)*

Co-organiser: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

---

### Educational Session

#### The changing faces of fungi

***Candida auris*: a growing threat**

*TBA*

***Blastomyces*: beyond an outbreak**

*Anastasia Litvintseva*

*(Atlanta, United States)*

**Update on *Scedosporium* & *Lomentospora***

*Fanny Lanternier (Paris, France)*

**Talk to me about Talaromycosis**

*Sirida Youngchim (Chang Mai, Thailand)*

---

### Educational Session

#### Rising to the challenge: new approaches to combat fungal infections and improve patient outcomes

**Fungal disease: the view of the patients**

*Rob Purdie (Bakersfield, United States)*

**Access to diagnosis of fungal disease: from the point of care to the diagnostic laboratory hub**

*Narda Medina (Guatemala, Guatemala)*

**Challenges in the treatment of fungal infections in LMICs**

*Nelesh Govender*

*(Johannesburg, South Africa)*

**Management of implant-associated fungal infections**

*Georgia Vrioni (Athens, Greece)*

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Implant-associated Infections (ESGIAI)

---

### Educational Session

#### Challenging infectious diseases among immigrant immunosuppressed patients

**Histoplasmosis**

*Ana Belen Arauz (Panama, Panama)*

**Chagas disease**

*TBA*

**Leishmaniasis**

*Johan van Griensven (Antwerp, Belgium)*

**Paracoccidioidomycosis**

*Rosane Hahn (Cuiaba, Brazil)*

---

### Educational Session

#### Ill travellers from around the globe: case-based approach

**Destination: Latin America**

*Carlos Seas (Lima, Peru)*

**Destination: Africa**

*Jose Muñoz (Barcelona, Spain)*

**Destination: Asia**

*Andreas Neumayr (Basel, Switzerland)*

**Destination: Boreal regions**

*TBA*

Co-organised with: Association of Medical Microbiology and Infectious Disease Canada (AMMI Canada)

# Preliminary Programme

## Educational Sessions

---

### Educational Session

#### Infection prevention and control (IPC) around the world - learning from each other

Challenges and practices for IPC: diverse populations, environment and pathogens  
*Rajalakshmi Ananthanarayanan (Trivandrum, India)*

Preventing surgical site infections  
*Peter Nthumba (Kijabe, Kenya)*

The role of the microbiology lab in IPC  
*Camilla Rodrigues (Mumbai, India)*

Surveillance of multidrug-resistant microorganisms  
*Anucha Apisarnthanarak (Bangkok, Thailand)*

Co-organised with: Clinical Infectious Diseases Society of India

---

### Educational Session

#### Environmental stewardship: cleaning the occupied bed space

How to clean the occupied patient room  
*Stepahine Dancer (Glasgow, United Kingdom)*

Are probiotic disinfectants effective in hospitals?  
*Elisabetta Caselli (Ferrara, Italy)*

Continuous UV-C light in the clinical environment  
*Curtis Donskey (Cleveland, United States)*

How to conduct real-life trials assessing hospital cleaning  
*Rasmus Leistner (Berlin, Germany)*

---

### Educational Session

#### Primer on infection prevention and control of multidrug-resistant Gram-negative bacilli

When to add an environmental contamination investigation: outbreaks and endemic situations  
*Lorena Lopes-Cerero (Sevilla, Spain)*

Treatment, prophylaxis and decolonisation of MDRGN carriers  
*Elena Carrara (Verona, Italy)*

Tailoring infection prevention strategies to cultural realities  
*Michael Borg (Msida, Malta)*

New infection prevention and control strategies  
*Nico Mutters (Bonn, Germany)*

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee

---

### Educational Session

#### *Clostridioides difficile* infection (CDI): managing complex cases

Severe case: to operate or not?  
*TBA*

Multiple recurrent CDI: where to you go when FMT is not an option?  
*Gianluca Ianiro (Rome, Italy)*

Live biotherapeutic products for recurrent CDI: what's new?  
*Elena Reigadas (Madrid, Spain)*

Friday of a bank holiday: CDI outbreak, now what?  
*Karen Burns (Dublin, Ireland)*

Co-organised with: ESCMID Study Group for *Clostridioides difficile* (ESGCD), ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI)

---

### Educational Session

#### Outbreaks in healthcare settings: practical guidance and case scenarios

**Influx of infections: case scenario and simulation exercise**

*Sotirios Tsiodras (Athens, Greece)*

**MDRO outbreak in hospitals: case scenario and simulation exercise**

*Bojana Beovic (Ljubljana, Slovenia)*

**Managing an outbreak of *Candida auris***

*Tanu Singhal (Maharashtra, India)*

**Prevention of endoscopy-related outbreaks**

*Lawrence Hookey (Kingston, Canada)*

Co-organised with: EUCIC Steering Committee

---

### Educational Session

#### ***Staphylococcus aureus*: from bench to bedside**

**New insights into *S. aureus* biology**

*Andreas Peschel (Tübingen, Germany)*

**Unravelling *S. aureus* intracellular lifestyles by phenotypic profiling**

*Ana Eulalio (London, United Kingdom)*

**Interactions of *S. aureus* with the immune system**

*Nina van Sorge*

*(Amsterdam, Netherlands)*

**Clinical trials of new and non-conventional approaches for *S. aureus* infections**

*Steven Tong (Surrey Hills, Australia)*

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

---

### Educational Session

#### Diagnostic and management dilemmas in immunocompromised hosts: you be the judge

**Invasive fungal infection prior to HSCT**

*Johan Maertens (Leuven, Belgium)*

**MDRO *Burkholderia* spp and lung transplantation**

*Saima Aslam (San Diego, United States)*

**Resistant CMV infection in a patient with immunodeficiency**

*Elisa Cordero (Seville, Spain)*

**Infections in decompensated cirrhosis**

*Salvatore Piano (Padua, Italy)*

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), European Association for the study of the liver (EASL)

---

### Educational Session

#### Infections and inborn errors of immunity. When to think and how to act

**Genetic predisposition for infectious diseases**

*TBA*

**When should an inborn error of immunity be suspected in an adult?**

*Siobahn Burns (London, United Kingdom)*

**Immunomodulatory therapy: when antibiotics are not enough**

*Steven Holland (Bethesda, United States)*

**Antimicrobial prophylaxis in patients with Inborn Errors of Immunity**

*Olaf Neth (Seville, Spain)*

Co-organised with: European Society of Immunodeficiencies

# Preliminary Programme

## Educational Sessions | Open Forum

---

### Educational Session

#### Clinical practice guidelines on ID: present and future

**Behind the curtain: how guidelines are made**

*Blin Nagavci (Gjakove, Kosovo)*

**IncOrPorating Ethics iN Clinical Guidelines: The ESCMID OPENING project**

*Elda Righi (Verona, Italy)*

**AI for Guideline development: opportunities and pitfalls**

*TBA*

**The future of guidelines: what's next**

*Jose Ramon Pano Pardo*

*(Zaragoza, Spain)*

Co-organised with: ESCMID Ethics Advisory Committee (EEAC), ESCMID Publication Subcommittee, ESCMID Guidelines Subcommittee

---

### Educational Session

#### AI tools transforming scientific research and communication

**Using generative AI in scientific research: opportunities and risks**

*TBA*

**AI shaping the future of scientific writing and publishing**

*Ursula Hofer (London, United Kingdom)*

**(Mis)information fuelled by AI tools**

*TBA*

**AI tools: does AI-generated text challenge the core values of research?**

*David B. Resnik (Durham, United States)*

Co-organised with: CMI Board of Editors

---

Open Forum

**Going green: infection and sustainability**

**Reduction of energy use in the lab**

*Rolf Slaats (Twente, Netherlands)*

**Sustainability and IPC: friend or foe?**

*Andreas Voss (Groningen, Netherlands)*

**Do we really need all these gloves?**

*Sarah Tschudin-Sutter*

*(Basel, Switzerland)*

Co-organised with: ESCMID Scientific Affairs Subcommittee, International Society of Antimicrobial Chemotherapy (ISAC)

---

Open Forum

**Research integrity in clinical microbiology and infectious diseases**

**Eliminating "helicopter research" in CM/ID**

*Nada Fadul (Omaha, United States)*

**Women's representation in clinical trials: between participants and PIs**

*Dafna Yahav (Ramat-Gan, Israel)*

**Women's authorship and editorship in CM/ID journals**

*Katharina Last (Bonn, Germany)*

**Informed consent: the balance between patient autonomy and broad representation of populations in trials**

*Muge Cevik (Edinburgh, United Kingdom)*

Co-organised with: CMI Board of Editors, ESCMID Ethics Advisory Committee (EEAC)

---

Open Forum

**Building capacity and addressing inequalities in AMR surveillance**

**Strengthening laboratory capacity in resource-limited settings for reliable AST results**

*Biljana Kakaraskoska Boceska*

*(Antwerp, Belgium)*

**Ten years of CAESAR EQA: achievements, challenges and unmet needs**

*Onur Karatuna (Växjö, Sweden)*

**How to foster equitable partnership and mentorship models in international collaborations in AMR**

*Muneera Rasheed (Karachi, Pakistan)*

**Ensuring patient representation and voice in AMR focused interventions**

*Oluchi Mbamalu*

*(Cape Town, South Africa)*

Co-organised with: CAESAR network, Dutch Society for Medical Microbiology (NVMM)

---

Open Forum

**Professional skills that enhance performance in CM/ID**

**Resilience and work engagement**

*Juanjo Beunza (Madrid, Spain)*

**Communication skills of physicians and patients' satisfaction**

*TBA*

**Communicating antibiotic prescribing to patients**

*TBA*

Co-organised with: Trainee Association of ESCMID (TAE) Steering Committee

# Preliminary Programme

## Open Forum | Year in Symposia

---

### Open Forum

#### Publishing in CM/ID: continuing challenges

**Caveat author: (semi-) predatory journals in CM/I**

*Leonard Leibovici (Petah-Tiqva, Israel)*

**Selecting the best journal: looking beyond impact factor**

*Cesar Arias (Houston, United States)*

**Pathways to overcome intersectoral disadvantage in scientific publication**

*Esayas Kebede (Jimma, Ethiopia)*

**The role of qualitative research in infectious diseases**

*Dena van den Bergh*

*(Cape Town, South Africa)*

Co-organised with: British Society for Antimicrobial Chemotherapy (BSAC), ESCMID Parity Commission

---

### Open Forum

#### Research barriers and enablers in CM/ID

**The European Data Health Space**

*Marieke Meijer (Brussels, Belgium)*

**Inter-continental collaborations: the Brazilian Pasteur experience**

*Marcio Rodrigues (Brasilia, Brazil)*

**Overcoming language barriers in research: a double jeopardy**

*Mehboob Mehboob (Swabi, Pakistan)*

**Barriers in training for quality research**

*Ibuchukwu Orabueze (Enugu, Nigeria)*

Co-organised with: Biomed Alliance, ESCMID Ethics Advisory Committee (EEAC), ESCMID Parity Commission

---

### Open Forum

#### AMS: a team sport involving all health professionals

**The contribution of nurses to Antimicrobial Stewardship**

*Maria Clara Padoveze (Sao Paulo, Brazil)*

**Embedding antimicrobial stewardship in integrated community case management programmes**

*Sorawat Sangkaew (Songkhla, Thailand)*

**Rational microbiological diagnostics for AMS**

*Brita Skodvin (Bergen, Norway)*

Co-organised with: ESCMID Study Group for Antimicrobial stewardship (ESGAP)

---

1-hour Symposium

Year in infectious diseases

*Oana Sandulescu (Bucharest, Romania)*

*Nur Benzonana (Istanbul, Turkey)*

---

1-hour Symposium

Year in public health

*Alexandra Mailles (Paris, France)*

*Ziad Memish (Riyadh, Saudi Arabia)*

---

1-hour Symposium

Year in clinical microbiology

*Patricia Munoz (Madrid, Spain)*

*Arjana Tambic Andrasevic  
(Zagreb, Croatia)*

---

1-hour Symposium

Year in infection control

*Stephan Juergen Harbarth  
(Geneva, Switzerland)*

*Elisabeth Presterl (Vienna, Austria)*